These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1953259)

  • 1. [Effects of deprivation and replacement by percutaneous 17 beta estradiol and oral progesterone on blood pressure and metabolic parameters in menopause patients with non-insulin-dependent diabetes].
    Mosnier-Pudar H; Faguer B; Guyenne TT; Tchobroutsky G
    Arch Mal Coeur Vaiss; 1991 Aug; 84(8):1111-5. PubMed ID: 1953259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism].
    Giuliani A; Concin H; Wieser F; Boritsch J; Wilfert H; Gruber D; Urdl W
    Wien Klin Wochenschr; 2000 Jul; 112(14):629-33. PubMed ID: 11008325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hormone therapy on the enteroinsular axis.
    Sztefko K; Rogatko I; Milewicz T; Józef K; Tomasik PJ; Szafran Z
    Menopause; 2005; 12(5):630-638. PubMed ID: 16145319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension.
    Spritzer PM; Vitola D; Vilodre LC; Wender MC; Reis FM; Ruschel S; Castro I
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):267-73. PubMed ID: 12951632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional adipose tissue metabolism in postmenopausal women after treatment with exogenous sex steroids.
    Lindberg UB; Crona N; Silfverstolpe G; Björntorp P; Rebuffé-Scrive M
    Horm Metab Res; 1990 Jun; 22(6):345-51. PubMed ID: 2116375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.
    Moorjani S; Dupont A; Labrie F; De Lignieres B; Cusan L; Dupont P; Mailloux J; Lupien PJ
    J Clin Endocrinol Metab; 1991 Aug; 73(2):373-9. PubMed ID: 1649840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.
    De Lignieres B; Basdevant A; Thomas G; Thalabard JC; Mercier-Bodard C; Conard J; Guyene TT; Mairon N; Corvol P; Guy-Grand B
    J Clin Endocrinol Metab; 1986 Mar; 62(3):536-41. PubMed ID: 3080464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women.
    Balci H; Altunyurt S; Acar B; Fadiloglu M; Kirkali G; Onvural B
    Maturitas; 2005 Apr; 50(4):289-93. PubMed ID: 15780528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of estradiol on blood lipids and lipoproteins in postmenopausal women.
    Fåhraeus L
    Obstet Gynecol; 1988 Nov; 72(5 Suppl):18S-22S. PubMed ID: 3173937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium.
    Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D
    Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J; Sumino H; Ichikawa S; Ozaki M
    Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.
    Perrone G; Stefanutti C; Galoppi P; Anelli G; Capri O; Lucani G; Vivenzio A; Mazzarella B; Zichella L
    Int J Fertil Menopausal Stud; 1996; 41(6):509-15. PubMed ID: 9010744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
    Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V
    Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.